Mesoblast limited Downgraded to “Hold” at Morningstar (MSB)
Mesoblast limited (ASX:MSB) was downgraded by stock analysts at Morningstar from an “accumulate” rating to a “hold” rating in a report issued on Wednesday, Stock Ratings Network.com reports. They currently have a $6.08 price objective on the stock.
Shares of Mesoblast limited (ASX:MSB) traded down 0.99% during mid-day trading on Wednesday, hitting A$6.000. 98,232 shares of the company’s stock traded hands. Mesoblast limited has a 1-year low of A$5.140 and a 1-year high of A$7.490. The stock’s 50-day moving average is A$5.84 and its 200-day moving average is A$5.84. The company’s market cap is A$1.879 billion.
Mesoblast Limited (ASX:MSB) is a clinical development company leveraging its core technologies, which include the Mesenchymal Precursor Cell (MPC) technology platform for bone marrow and adipose tissue derived products, Dental Pulp Stem Cells (DPSCs), and expanded Hematopoietic Stem Cells (HSCs).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.